Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-XACP3 PET/CT in Prostate Cancer
Sponsor: The First Affiliated Hospital of Xiamen University
Summary
The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET/CT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET/CT.
Official title: PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer and Compared With 68Ga-PSMA
Key Details
Gender
MALE
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-09-01
Completion Date
2027-10-01
Last Updated
2025-11-21
Healthy Volunteers
No
Conditions
Interventions
Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET/CT), 68Ga-XACP3 PET/CT
Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (68Ga-PSMA) and 68Ga-XACP3, and undergoes PET/CT imaging within the specified time.
Locations (1)
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China